SELVEDge
Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma (SELVEDge)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 33 patients (estimated)
- Sponsors
- University of Miami
- Collaborators
- Karyopharm Therapeutics
- Tags
- BCL-2 Inhibitor, Selective Inhibiton of Nuclear Export (SINE)
- Trial Type
- Treatment
- Last Update
- 4 months ago
- SparkCures ID
- 1309
- NCT Identifier
- NCT05530421
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.